The international expert consensus on management of external auditory canal carcinoma.

Autor: Zhou P; Department of Otology and Skull Base Surgery, Eye Ear Nose and Throat Hospital, Fudan University, 83 Fenyang Road, Shanghai, 200031, China.; Key Laboratory of Hearing Medicine, Eye Ear Nose and Throat Hospital, Ministry of Health, Fudan University, 83 Fenyang Road, Shanghai, 200031, China., de Brito R; Department of Otorhinolaryngology, University of São Paulo School of Medicine, São Paulo, Brazil., Cui Y; Department of Otolaryngology-Head and Neck Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Lloyd S; University Department of Otolaryngology Head and Neck Surgery, Peter Mount House, Manchester Royal Infirmary, Manchester, UK., Kunst H; Department of Otorhinolaryngology, Hearing and Genes, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Otorhinolaryngology, Dutch Academic Alliance Skull Base Pathology, Maastricht University Medical Center, Maastricht, The Netherlands., Kutz JW; Department of Otolaryngology-Head and Neck Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA., Mani N; Department of Otolaryngology, Manchester University Hospitals NHS Foundation Trust, Manchester, UK., Moon IS; Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Korea., Mostafa BE; Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medicine, Ain-Shams University, Cairo, Egypt., Nabuurs C; Department of Otorhinolaryngology, Hearing and Genes, Radboud University Medical Center, Nijmegen, The Netherlands., Rao SCP; Department of Otolaryngology, Kasturba Medical College, Manipal University, Head & Neck Surgery, Mangalore, Karnataka, India., Xie B; Department of Otolaryngology Head and Neck Surgery, the Second Affiliated Hospital of Nanchang University, Nanchang, China., Zhang Y; Department of Otology and Skull Base Surgery, Eye Ear Nose and Throat Hospital, Fudan University, 83 Fenyang Road, Shanghai, 200031, China.; Key Laboratory of Hearing Medicine, Eye Ear Nose and Throat Hospital, Ministry of Health, Fudan University, 83 Fenyang Road, Shanghai, 200031, China., Dai C; Department of Otology and Skull Base Surgery, Eye Ear Nose and Throat Hospital, Fudan University, 83 Fenyang Road, Shanghai, 200031, China. cfdai66@126.com.; Key Laboratory of Hearing Medicine, Eye Ear Nose and Throat Hospital, Ministry of Health, Fudan University, 83 Fenyang Road, Shanghai, 200031, China. cfdai66@126.com.
Jazyk: angličtina
Zdroj: European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery [Eur Arch Otorhinolaryngol] 2024 Oct 28. Date of Electronic Publication: 2024 Oct 28.
DOI: 10.1007/s00405-024-09033-w
Abstrakt: Purpose: The objective of this consensus is to provide otolaryngologists with appropriate strategies in the management of external auditory canal (EAC) carcinoma.
Methods: In the absence of randomized controlled trials, the consensus is based on expert opinions utilizing the Rand/UCLA appropriateness method [Fitch and Aguilar in The RAND/UCLA appropriateness method user's manual, RAND Corporation, Santa Monica, CA, 2001], drawing from existing literature and clinical experience.
Results: The management recommendations are structured around 12 key areas, including: definition and pathology, pathogenesis, clinical manifestations, work-up, tumor staging system, surgical management of primary tumor, surgical management of the parotid gland and the temporomandibular joint, lymph node metastasis, radiotherapy, chemotherapy, reconstruction, and follow-up.
Conclusion: Management strategies for EAC carcinoma rely on tumor extension and histopathological features. Surgical removal with free surgical margins or combination with radiotherapy, chemotherapy are most often the best options. Given the rarity of the disease, prospective, randomized, multi-institutional clinical trials should be designed to enable reliable comparisons of the outcomes of EAC carcinoma treatments, thereby providing evidence-based clinical data to establish widely accepted guidelines. It emphasizes the need for a multidisciplinary team to be involved in the management of EAC carcinoma, and regular follow-up should be implemented postoperatively.
(© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: